Decision-Ready Proteomics for Modern Drug Discovery

Our latest white paper reveals how industrial-scale, mass spectrometry-based proteomics can help you accelerate discovery, reduce risk, and unlock new therapeutic opportunities.

Why this matters for you:

Traditional approaches often fail to address complex targets. Our platforms deliver unbiased, proteome-wide insights that enable smarter decisions and faster progression from hit to lead.

Inside the white paper:

• ScreenPep™ 2.0: High-throughput, ultra-deep proteome profiling for precise quantification of 10,000+ proteins per sample—ideal for large-scale screening.
• HT-ABPP & HT-PALMS: Identify covalent and reversible ligands directly in human cells, mapping ligandable sites across the proteome.
• Fragment-Based Innovation: Discover novel binders and E3 ligase recruiters for targeted protein degradation (TPD) and stabilization (TPS).
• Real-world case studies: Practical examples of accelerating first-in-class therapeutics. —

Your benefit:

Gain a competitive edge with scalable solutions that de-risk early discovery, expand druggable space, and enable breakthrough therapies.